Macrophage Activation Syndrome in Adults: Characteristics, Outcomes, and Therapeutic Effectiveness of Etoposide-based Regimen

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Oct 3

PMID 36189240

Authors

Lingbo He

Shuyan Yao

Ruoxi Zhang

Menghan Liu

Zhengjie Hua

Heshan Zou

Zhao Wang

Yini Wang

Affiliations

Soon will be listed here.

Abstract

Objectives: To describe the clinical characteristics and outcomes of adult macrophage activation syndrome (MAS) patients and to provide experience for the treatment.

Methods: Adult patients with MAS admitted to Beijing Friendship Hospital from December 2014 to September 2021 were enrolled in this study. Clinical data of patients were collected and analyzed.

Results: A total of 118 adult MAS patients entered this study. MAS was the first manifestation in 43 (36.4%) patients, while 75 (63.6%) developed MAS after the diagnosis of autoimmune disease (AID) with a median diagnostic interval of 2 (0.5-359) months. Eighty-two patients were initially treated with glucocorticoid-based regimen; the overall response (OR) rate at the 2-week posttreatment was 37.8%. Forty-five patients switched to etoposide-based regimen, and the OR rate was 84.4%. Thirty-six patients were initially treated with etoposide-based regimen, and the OR rate at the 2-week posttreatment was 80.6%. Serum IL-18 (P = 0.021), IFN-γ (P = 0.013), IP-10 (P = 0.001), IL-10 (P = 0.041), IL-1RA (P < 0.001), and TNF-α (P = 0.020) levels of patients were significantly decreased in the remission phase than in the active phase. Levels of SDF-1α (P = 0.018) and IL-7 (P = 0.022) were higher in refractory patients, while the GRO-α level had a strong tendency toward statistical significance (P = 0.050). The probability of overall survival (OS) at 3, 6, and 36 months after HLH diagnosis were 89.8%, 89.0%, and 87.9%, retrospectively. The active MAS status at the 2-week post initial treatment [P = 0.009, HR = 15.281, 95% CI, (0.1.972, 118.430)] and baseline neutrophil count (Neu) <1.5 × 10/l [P = 0.017, HR = 3.678, 95% CI, (1.267, 10.672)] were negative prognostic factors.

Conclusion: MAS typically occurs within 2 months after the onset of autoimmune disease in adults. SDF-1α, IL-7, and GRO-α could be used to predict refractory MAS. The etoposide-based regimen is effective and tolerable for adult MAS.

Citing Articles

Assessing the effectiveness of etoposide treatment in adult haemophagocytic lymphohistiocytosis: a systematic review and meta-analysis.

Gao T, Suolitiken D, Yang C, Wu C, He L, Wang Y Clin Exp Med. 2025; 25(1):58.

PMID: 39955467 PMC: 11829903. DOI: 10.1007/s10238-025-01570-w.

Successful management of infection and macrophage activation syndrome patient using low-dose etoposide: A case report.

Gao S, Luo X, Kosari M, Li W, Yang L, Tu W World J Radiol. 2024; 16(10):579-585.

PMID: 39494131 PMC: 11525825. DOI: 10.4329/wjr.v16.i10.579.

The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease.

Yin D, Wang J, Wang Z Ann Hematol. 2024; 103(9):3463-3472.

PMID: 38772957 DOI: 10.1007/s00277-024-05796-8.

Early identification of macrophage activation syndrome secondary to systemic lupus erythematosus with machine learning.

Lin W, Xie X, Luo Z, Chen X, Cao H, Fang X Arthritis Res Ther. 2024; 26(1):92.

PMID: 38725078 PMC: 11080238. DOI: 10.1186/s13075-024-03330-9.

Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.

Chen S, Zhang C, Chen D, Dong L, Chang T, Tang Z Front Immunol. 2023; 14:1200289.

PMID: 37483597 PMC: 10358730. DOI: 10.3389/fimmu.2023.1200289.

References

Al-Samkari H, Berliner N . Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2017; 13:27-49. DOI: 10.1146/annurev-pathol-020117-043625. View

Mizuta M, Shimizu M, Irabu H, Usami M, Inoue N, Nakagishi Y . Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatology (Oxford). 2020; 60(1):231-238. DOI: 10.1093/rheumatology/keaa299. View

Nigrovic P, Mannion M, Prince F, Zeft A, Rabinovich C, van Rossum M . Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011; 63(2):545-55. DOI: 10.1002/art.30128. View

Carter S, Tattersall R, Ramanan A . Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2018; 58(1):5-17. DOI: 10.1093/rheumatology/key006. View

Ke Y, Lv C, Xuan W, Wu J, Da Z, Wei H . Clinical analysis of macrophage activation syndrome in adult rheumatic disease: A multicenter retrospective study. Int J Rheum Dis. 2020; 23(11):1488-1496. DOI: 10.1111/1756-185X.13955. View

Coppola C, Hopkins B, Huhn S, Du Z, Huang Z, Kelly W . Investigation of the Impact from IL-2, IL-7, and IL-15 on the Growth and Signaling of Activated CD4 T Cells. Int J Mol Sci. 2020; 21(21). PMC: 7659484. DOI: 10.3390/ijms21217814. View

Horne A, von Bahr Greenwood T, Chiang S, Meeths M, Bjorklund C, Ekelund M . Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome-Hemophagocytic Lymphohistiocytosis. J Rheumatol. 2021; 48(10):1596-1602. DOI: 10.3899/jrheum.200941. View

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View

Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A . 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation.... Arthritis Rheumatol. 2015; 68(3):566-76. DOI: 10.1002/art.39332. View

10.

Kumakura S, Murakawa Y . Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol. 2014; 66(8):2297-307. PMC: 4271677. DOI: 10.1002/art.38672. View

11.

Miettunen P, Narendran A, Jayanthan A, Behrens E, Cron R . Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2010; 50(2):417-9. DOI: 10.1093/rheumatology/keq218. View

12.

Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G . Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2016; 76(1):166-172. DOI: 10.1136/annrheumdis-2015-209020. View

13.

Minoia F, Davi S, Horne A, Demirkaya E, Bovis F, Li C . Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014; 66(11):3160-9. DOI: 10.1002/art.38802. View

14.

Janka G, Lehmberg K . Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013; 2013:605-11. DOI: 10.1182/asheducation-2013.1.605. View

15.

Desmond R, Townsley D, Dumitriu B, Olnes M, Scheinberg P, Bevans M . Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2013; 123(12):1818-25. PMC: 3962161. DOI: 10.1182/blood-2013-10-534743. View

16.

Henter J, Elinder G, Soder O, Hansson M, Andersson B, Andersson U . Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991; 78(11):2918-22. View

17.

Wafa A, Hicham H, Naoufal R, Hajar K, Rachid R, Souad B . Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients. Clin Rheumatol. 2022; 41(7):2021-2033. DOI: 10.1007/s10067-022-06055-9. View

18.

Sonmez H, Demir S, Bilginer Y, Ozen S . Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018; 37(12):3329-3335. DOI: 10.1007/s10067-018-4095-1. View

19.

Grom A, Horne A, De Benedetti F . Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016; 12(5):259-68. PMC: 5851441. DOI: 10.1038/nrrheum.2015.179. View

20.

Ravelli A, Grom A, Behrens E, Cron R . Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012; 13(4):289-98. DOI: 10.1038/gene.2012.3. View